| answer text |
<p>This Government wants England to lead the world in tackling cancer and ensure the
National Health Service is able to meet the needs of all cancer patients. That is
why our 2011 Cancer Outcomes Strategy set the ambition to save a further 5,000 lives
a year from cancer by 2014-15. The Strategy is backed with more than £750 million
over the four year Spending Review period (2011-12 to 2014-15).</p><p> </p><p>A number
of treatments have been recommended by the National Institute for Health and Care
Excellence (NICE) for the treatment of gastrointestinal stromal tumour (GIST) including
the paediatric, adolescent, wild-type and syndromic (PAWS) sub-variants.</p><p> </p><p>NHS
commissioners are legally required to fund treatments recommended by NICE in its technology
appraisal guidance. NICE regularly reviews its guidance to take into account new evidence.</p><p>
</p><p>Treatment for PAWS GIST is commissioned through NHS England’s Specialised Services.
Treatment for individuals is managed through multi-disciplinary teams. GIST Support
UK have in partnership with Addenbrookes Hospital in Cambridge, established a PAWS-GIST
clinic that is led by Dr Bulusu working with a United Kingdom national alliance of
doctors. NHS England, through its Children’s Cancer and Sarcoma Clinical Reference
Groups, is monitoring the clinic as it develops and progresses.</p><p> </p><p>We know
how important it is for patients to receive the information they need and a range
of initiatives have been used in the NHS, such as information prescriptions, advanced
communications training and support for clinical nurse specialists.</p><p> </p><p>NICE
guidance on improving outcomes in children and young people with cancer also emphasises
the importance of providing patients, families and carers with the information they
need.</p><p> </p><p>NHS England has no plans to develop a National Service Framework
for paediatric, adolescent, wild-type and syndromic gastrointestinal stromal tumour.</p>
|
|
